BACKGROUND: There is increasing evidence that the immune system produces a humoral response to cancer-derived antigens. This study assessed the diagnostic potential of autoantibodies to multiple known tumour-associated proteins. PATIENTS AND METHODS: Sera from normal controls (n = 94), primary breast cancer patients (n = 97) and patients with ductal carcinoma in situ (DCIS) (n = 40) were investigated for the presence of autoantibodies to p53, c-myc, HER2, NY-ESO-1, BRCA1, BRCA2 and MUC1 antigens by enzyme-linked immunosorbent assay. RESULTS: Reproducibly elevated levels of autoantibodies were seen in at least one of the six antigens in 64% of primary breast cancer patient sera and 45% of patients with DCIS at a specificity of 85%. No significant differences were seen when patients were subdivided by age, tumour size, histological grade, lymph node status or detection methodology. CONCLUSIONS: Autoantibodies against one or more of these tumour-associated antigens appears to indicate the presence of early-stage breast cancers. Autoantibody assays against a panel of antigens could be used as an aid to mammography in the detection and diagnosis of early primary breast cancer, especially in younger women at increased risk of breast cancer where mammography is known to have reduced sensitivity and specificity.
BACKGROUND: There is increasing evidence that the immune system produces a humoral response to cancer-derived antigens. This study assessed the diagnostic potential of autoantibodies to multiple known tumour-associated proteins. PATIENTS AND METHODS: Sera from normal controls (n = 94), primary breast cancerpatients (n = 97) and patients with ductal carcinoma in situ (DCIS) (n = 40) were investigated for the presence of autoantibodies to p53, c-myc, HER2, NY-ESO-1, BRCA1, BRCA2 and MUC1 antigens by enzyme-linked immunosorbent assay. RESULTS: Reproducibly elevated levels of autoantibodies were seen in at least one of the six antigens in 64% of primary breast cancerpatient sera and 45% of patients with DCIS at a specificity of 85%. No significant differences were seen when patients were subdivided by age, tumour size, histological grade, lymph node status or detection methodology. CONCLUSIONS: Autoantibodies against one or more of these tumour-associated antigens appears to indicate the presence of early-stage breast cancers. Autoantibody assays against a panel of antigens could be used as an aid to mammography in the detection and diagnosis of early primary breast cancer, especially in younger women at increased risk of breast cancer where mammography is known to have reduced sensitivity and specificity.
Authors: Karen S Anderson; Sahar Sibani; Garrick Wallstrom; Ji Qiu; Eliseo A Mendoza; Jacob Raphael; Eugenie Hainsworth; Wagner R Montor; Jessica Wong; Jin G Park; Naa Lokko; Tanya Logvinenko; Niroshan Ramachandran; Andrew K Godwin; Jeffrey Marks; Paul Engstrom; Joshua Labaer Journal: J Proteome Res Date: 2010-11-23 Impact factor: 4.466
Authors: Jung-Rok Lee; D James Haddon; Nidhi Gupta; Jordan V Price; Grace M Credo; Vivian K Diep; Kyunglok Kim; Drew A Hall; Emily C Baechler; Michelle Petri; Madoo Varma; Paul J Utz; Shan X Wang Journal: ACS Nano Date: 2016-09-20 Impact factor: 15.881
Authors: Pavel Gromov; Irina Gromova; Jakob Bunkenborg; Teresa Cabezon; José M A Moreira; Vera Timmermans-Wielenga; Peter Roepstorff; Fritz Rank; Julio E Celis Journal: Mol Oncol Date: 2009-11-23 Impact factor: 6.603